<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432949</url>
  </required_header>
  <id_info>
    <org_study_id>17-5196</org_study_id>
    <nct_id>NCT03432949</nct_id>
  </id_info>
  <brief_title>Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC</brief_title>
  <acronym>TRANCE</acronym>
  <official_title>Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) no&#xD;
      longer responding to androgen deprivation hormonal therapy have evidence of bone metastases.&#xD;
      This is a major cause of death, disability, and decreased quality of life.&#xD;
&#xD;
      Radium-223 is radiopharmaceutical meaning that the drug is a radioactive compound used for&#xD;
      therapeutic purposes. It is given intravenously (through a vein) every 4 weeks for 6 cycles.&#xD;
      Research has demonstrated safety and efficacy in mCRPC patients resulting in radium-223&#xD;
      becoming a standard of care option for such patients in addition to chemotherapy and new oral&#xD;
      hormonal drugs enzalutamide or abiraterone.&#xD;
&#xD;
      Prior research studies using radium-223 have shown improved survival in about 30% of&#xD;
      patients. The same studies in combination with data collected from clinical use have also&#xD;
      shown that between 20 and 50% of men do not complete the full 6 cycle course of treatment due&#xD;
      to side effects or a rise in prostate specific antigen (PSA) requiring the stoppage of&#xD;
      radium-223 therapy to start one of the other drug therapies.&#xD;
&#xD;
      The purpose of this study is to determine whether an oral drug called dexamethasone (a&#xD;
      corticosteroid) given together with radium-223 may control PSA levels and reduce side effects&#xD;
      during radium-223 treatment. Corticosteroids are anti-inflammatory medicines prescribed for a&#xD;
      broad range of conditions and are widely used in conjunction with chemotherapy treatments for&#xD;
      cancer. Prior research studies have shown that dexamethasone reduces PSA levels by lowering&#xD;
      the production of androgens (i.e. male hormones) and improves overall tolerance for&#xD;
      cancer-fighting drugs and therapies.&#xD;
&#xD;
      Up to 24 men being treated with radium-223 at University Health Network will be enrolled into&#xD;
      this study. If the study is positive, it might offer an improved quality of life and extended&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of total doses delivered on schedule</measure>
    <time_frame>Through infusion completion, an average of 24 weeks</time_frame>
    <description>To assess the feasibility of delivering 6-treatment cycles of Radium-223 without delays when administered in combination with low-dose oral dexamethasone for patients with metastatic CRPC and bony metastases who are abiraterone, enzalutamide and systemic chemotherapy naïve.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Standard of Care Radium-223</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Radium-223 treatment will be administered as per standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium-223 with oral Dexamethasone 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone plus Radium-223</intervention_name>
    <description>Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.</description>
    <arm_group_label>Radium-223 with oral Dexamethasone 0.5 mg</arm_group_label>
    <other_name>Dexamethasone</other_name>
    <other_name>Baycadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Clinical diagnosis of prostate cancer&#xD;
&#xD;
          2. ECOG status ≤ 2&#xD;
&#xD;
          3. PSA ≥ 2.0 ng/mL&#xD;
&#xD;
          4. Rising PSA in combination with new metastases or evidence of radiographic disease&#xD;
             progression despite castrate levels of testosterone while on androgen deprivation&#xD;
             therapy (ADT) or following bilateral orchiectomy&#xD;
&#xD;
          5. Symptomatic disease defined as any analgesic use for pain or receipt of radiotherapy&#xD;
             for bony metastatic disease&#xD;
&#xD;
          6. Adequate renal and hepatic function:&#xD;
&#xD;
               -  Cr ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  AST ≤ 2.5 x ULN&#xD;
&#xD;
               -  ALT ≤ 2.5 x ULN&#xD;
&#xD;
               -  Albumin &gt; 25 g/L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          7. Adequate hematologic function&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 100 g/L&#xD;
&#xD;
          8. Evidence of bone metastasis on bone scan, CT, MRI or PET&#xD;
&#xD;
          9. Life expectancy ≥ 6 months&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Visceral metastatic PCa (brain, liver, lung, bulky adenopathy). Note that metastatic&#xD;
             lymphadenopathy &lt; 3cm is acceptable for inclusion as long as there is evidence of bone&#xD;
             metastasis.&#xD;
&#xD;
          2. Previous treatment with abiraterone, enzalutamide, docetaxel or other systemic&#xD;
             chemotherapy for PCa&#xD;
&#xD;
          3. Imminent spinal cord compression or history of spinal cord compression&#xD;
&#xD;
          4. Previous treatment with systemic corticosteroids for PCa at any time&#xD;
&#xD;
          5. Contraindication to receipt of systemic corticosteroids (i.e. uncontrolled diabetes)&#xD;
&#xD;
          6. Prior or current enrolment in any other interventional clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heidi Wagner</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>2354</phone_ext>
    <email>heidi.wagner@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miran Kenk</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>3431</phone_ext>
    <email>miran.kenk@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Wagner</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2354</phone_ext>
      <email>heidi.wagner@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Neil Fleshner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathan Perlis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Hamilton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Girish Kulkarni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Zlotta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Finelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Srikala Sridhar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radium-223</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>mCRPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

